NCT03938337终止2 期
Clinical Trial of Abemaciclib in Combination With Pembrolizumab in Patients With Metastatic or Recurrent Head and Neck Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- To Assess the Objective Response Rate of Tumor Lesions Using Scans
研究概览
简要总结
To assess the objective response rate of tumor lesions to abemaciclib in combination with pembrolizumab in patients with metastatic or recurrent squamous cell carcinoma of head and neck.
详细描述
Immunotherapy has been recently approved for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. However, only a small percentage of patients experience long-term control, necessitating new therapeutic strategies. Recently, it was shown preclinically and in breast tumors that abemaciclib stimulates production of type III interferons and hence enhances tumor antigen presentation. Abemaciclib also suppressed the proliferation of regulatory T cells. These events promote cytotoxic T-cell-mediated clearance of tumor cells, which is further enhanced by the addition of immune checkpoint blockade. Based on these data, a phase II trial in patients with metastatic or recurrent head and neck cancer who are eligible for immunotherapy is proposed to investigate the combination of abemaciclib with pembrolizumab. Tumor & blood analysis for interferon gamma signature will be explored as possible biomarkers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed (core biopsy proven) metastatic or recurrent squamous cell carcinoma of head and neck
- •Adequate pulmonary and cardiac function
- •Available archived tissue of primary tumor or resected tumor specimen with adequate samples
- •Prior treatment with immune checkpoint inhibitor is not allowed in cohort 1 patients. Patients in cohort 2 should have failed or progressed on prior immune checkpoint inhibitor
- •Eastern Cooperative Oncology Group Performance Status(ECOG PS) = 0 or 1
- •Patients who received chemotherapy must have recovered (Common Terminology Criteria for Adverse [CTCAE] Grade <= 1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to randomization. A washout period of at lease 21 days is required between last chemotherapy dose and randomization (provided the patient did not receive radiotherapy)
- •Patients who received adjuvant radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and randomization
- •The patient is able to swallow oral medications
- •Adequate hematologic and end-organ function
- •Absolute Neutrophil Count (ANC) >= 1500/mm3
- •Platelet count ≥ 100,000/mm3
- •Hemoglobin (Hb) ≥ 8g/dl (Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion)
- •Creatinine (Cr) ≤ 1.5 x Upper Limit of Normal (ULN) or Creatinine Clearance (CrCl) ≥ 60 ml/min
- •Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert syndrome, who can have total Bilirubin < 2.0 x ULN and direct bilirubin within normal limits are permitted.)
- •Aspartate Aminotransferase (AST) and Alanine aminotransferase (ALT) and alkaline phosphatase ≤ ULN
- •Agreement to remain abstinent or use appropriate contraception, among women of childbearing potential
- •Willingness and ability to consent for self to participate in study
- •Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
排除标准
- •Autoimmune disease (Note: Vitiligo, type 1 diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, and conditions not expected to recur in the absence of an external trigger are permitted.)
- •Condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to study treatment (Note: Inhaled and topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.)
- •Preexisting medical condition(s) that would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).
- •Immunosuppression, of any kind
- •Prior treatment with Cyclin-Dependent Kinase(CDK) 4/6 Inhibitor
- •Major surgical procedure or significant traumatic injury within 4 weeks prior to study treatment, and must have fully recovered from any such procedure
- •Personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest
- •Angina, myocardial infarction (MI), symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack TIA), arterial embolism, pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass grafting (CABG) within 6 months prior to study treatment
- •Known active viral or non-viral hepatitis or cirrhosis
- •Any active infection requiring systemic treatment, positive tests for Hepatitis B surface antigen or Hepatitis C ribonucleic acid (RNA).
- •History of gastrointestinal perforation or fistula in the 6 months prior to study treatment, unless underlying risk has been resolved (e.g., through surgical resection or repair)
- •Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness
- •Pregnancy or breastfeeding - Female patients must be surgically sterile (i.e., ≥6 weeks following surgical bilateral oophorectomy with or without hysterectomy or tubal ligation) or be postmenopausal, or must agree to use effective contraception during the study and for 4 months following last dose of treatment. All female patients of reproductive potential must have a negative pregnancy test (serum or urine) within 7 days prior to study treatment. Male patients must be surgically sterile or must agree to use effective contraception during the study and for 4 months following last dose of treatment.
- •Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for this study
研究组 & 干预措施
Cohort 2 Treated Previously
Experimental
Patients with metastatic or recurrent head and neck cancer who have been treated previously with immunotherapy.
干预措施: Cohort 2 Treated Previously (Drug)
Cohort 1 Not Previously Treated
Experimental
Patients with metastatic or recurrent head and neck cancer who have not been treated previously with immunotherapy.
干预措施: Cohort 1 Not Previously Treated (Drug)
结局指标
主要结局
To Assess the Objective Response Rate of Tumor Lesions Using Scans
时间窗: Baseline to 8 months
Patients will be evaluated for their tumor response to treatment using RECIST criteria on their scans
次要结局
- Number of Participants Experiencing Adverse Events Grade 3 or Greater(Baseline to 12 months)
- To Assess the Time to Tumor Response(baseline to 12 months)
- To Assess the Duration of Response(baseline to 12 months)
- To Assess Progression Free Survival (PFS)(baseline to 12 months)
- To Assess Overall Survival(baseline to 12 months)
研究者
Eddy Yang
Primary Investigator
University of Alabama at Birmingham
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast CancerNon Small Cell Lung CancerBreast CancerNCT02779751Eli Lilly and Company100
撤回
2 期
Abemaciclib + Pembrolizumab In GlioblastomaGlioblastomaNCT04118036Dana-Farber Cancer Institute
已完成
1 期
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including NeuroblastomaRelapsed Solid TumorRefractory Solid TumorNCT04238819Eli Lilly and Company47
已完成
2 期
Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid CancerAnaplastic Thyroid CancerUndifferentiated Thyroid CancerThyroid CancerNCT04552769Stanford University9
终止
2 期
Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate CancerProstate CancerNCT04298983University of Alabama at Birmingham9